TopoTarget
- Company overview
- TopoTarget is a Danish biotech company focused on cancer and other cancer-related disorders. It has five clinical development programmes. The lead product, belinostat, is in 19 mid-stage clinical studies (11 of which are sponsored by the NCI).
| Date | Reports available | Download |
|---|---|---|
| Feb 09 2010 |
Belinostat deal TopoTarget’s co-development deal with Spectrum Pharmaceuticals for its HDAC inhibitor belinostat, signed last week, looks to be a transformative event for the Danish biotech company. The $30m upfront should provide at least two years’ cash, taking it comfortably beyond the potential approval in PTCL (where filing is expected in 2011). Spectrum will pay up to $350m in milestones (mostly sales-related), double-digit royalties and fund 70% of future development costs in exchange for US and Indian rights. Research type: QuickView |
Log in to download 2 page note available |
- Register free to access the latest research.
- Contact us to find out how we help companies reach their investors.
IN THIS SECTION
Keep updated
Would you like to be notified when new research is published? Access our research RSS feed
Edison's research ... is balanced, objective and provides a level of detail not normally associated with smaller companies.
Peter Knowles
Director, Fyshe Horton Finney